PubMed Health⌕ Search

Biomedical subjects

R Usheva

Publications and source records attributed to R Usheva.

8 recordsLinked to original sources
PubMed1988

[Information value of isoelectric focusing of serum proteins in non-Hodgkin's lymphomas].

The importance of isoelectric focusing of serum proteins was studied in 35 patients with non-Hodgkin lymphoma: multiple myeloma--10 patients, chronic lymphatic leukemia--5 patients, other non-Hodgkin malignant lymphoma--20 patients. 30 clinically healthy persons were also examined as controls. By isoelectric focusing the images with monoclonal immunoglobulins differ from those with polyclonal immunoglobulins. Using this method paraproteinemia was found in 19 patients (54%): in all patients with multiple myeloma 2 patients with chronic lymphatic leukemia and 3 patients with other non-Hodgkin malignant lymphoma. By electrophoresis on cellulose acetate folia paraprotein was found in 13 patients only. In the remaining patients, in whom monoclonal immunoglobulin was found only by isoelectric focusing, the electrophoresis, total serum protein, IgA and IgM did not show pathologic deviations. The IgG values were normal or borderline. The isoelectric focusing exceeds the other methods in informative value. Further study is necessary in order to confirm the diagnostic and prognostic value of isoelectric focusing in non-Hodgkin malignant lymphoma.

Adult↗
PubMed1988

[Second neoplasms in malignant hemopathies].

12 cases of a second malignant neoplasm in patients with a systemic hematologic disease were for a 10-year-period among the patients of a hematologic clinic. Seven of these cases are reported in detail. The factors which lead to this phenomenon becoming more frequent are discussed.

Adult↗
PubMed1987

[Prognostic value of thrombocytopenia in myeloma].

The incidence, severity and prognostic value of thrombocytopenia were studied in 80 patients with myeloma in connection with the clinical stage of the disease and the reaction to the cytostatic treatment. The studies were carried out before the treatment and followed up in the course of the treatment to remission or absence of remission. The results established a progressing thrombocytopenia with the evolution of the disease. Severe thrombocytopenia was established only in stage III, being with an unfavourable prognosis as regards the therapeutic response. The pathogenetic mechanism of its origination are discussed--malignant process in bone marrow, renal insufficiency, advancement of DIC syndrome and toxic effect by the cytostatics administered.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1986

[Incidence and forms of the DIC syndrome in multiple myeloma].

The incidence and forms of DIC-syndrome were studied in 80 patients with myeloma. A battery of hemostatic tests was used, allowing the diagnosis of both the chronic decompensated and compensated forms. The syndrome has been established in 29% of the non-treated patients and becomes more frequent with the advancing of the clinical stage of the disease. Several patients with a rather special clinical course are described. The treatment of the syndrome coincides with the treatment of the basic disease and the concomitant complications, and heparin was administered only in single cases. The pathogenetic mechanisms for advancing of DIC in myeloma are described, associated with the character and peculiarities of the basic disease.

Blood Coagulation Tests↗
PubMed1976

[Comparative clinical studies of the effectiveness of the most frequently used antibiotics in the period of 1961-1970].

The results from the treatment of 1086 patients, treated at the Therapeutic Clinic, HMI- Sofia were followed up for the period 1961-1970 incld. Acute bacterial and vuris-bacterial pneumonias were found in 318 patients, 475 of the patients were with exacerbated chronic bronchitis and bronchiectasis, with exacerbated chronic pyelo-nephritis -216 patients and with exacerbated chronic cholecystitis and cholangiohepatitis --92 patients. The effect of the treatment was determined according to a three-stage scale "good" with complete clinical healing (in acute pneumonia), with "improvement"--with complete clinical remission (in chronic infections) and "without effect". Clinical and paraclinical indices were used as criteria in the determination of the effectiveness. The data are statistically processed according to the method of variation analysis. In patients with acute pneumonia the- best effectiveness was manifested by tetraolean (88,7 per cent), tetracylins (77,8 per cent), chloramphenicol (76,8 per cent), penicillin (72,5 per cent), the combination penicillin-streptomycin (71,9 per cent); in patients with exacerbated chronic bronchitis--tetraolean (88,0 per cent), chloramphenicol (73,2 per cent), tetracylins (65,3 per cent); in patients with exacerbated chronic pyelonephritis - chloramphenicol (65,5 per cent); in patients with exacerbated chronic cholecystitis and cholecysto-cholangiohepatitis-tetraolean (70,7 per cent), tetracyclins (66,7 per cent), chloramphenicol (66,1 per cent).

Acute Disease↗